Form D · Biotechnology
RevOpsis Therapeutics, Inc.
Springfield, IL · CIK 0001939796
Offering snapshot reported Nov 7, 2024 · SEC filing
- Reported sold
- $575K Indefinite offering
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $25K Reported outside-investor minimum
- First sale
- Oct 24, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 7, 2024 | Initial | $575,000 | No comparison | 4 | SEC filing |
| Aug 10, 2023 | Initial | $7,895,004 | No comparison | 36 | SEC filing |
| Aug 24, 2022 | Initial | $100,000 | No comparison | 1 | SEC filing |
| Jul 29, 2022 | Initial | $0 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-528924
SAFE (Simple Agreement for Future Equity)
Source: Form D, filed Nov 7, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Ramanath Bhandari | Executive |
| Jeff Olson | Director |
| Ram Palanki | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
4109 Chandlerwood
Springfield, IL, 62711
Springfield, IL, 62711